DelveInsight’s, “Gastric Cancer Pipeline Insight 2024” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Gastric Cancer Pipeline Report

• DelveInsight’s Gastric Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Gastric Cancer treatment.
• The leading Gastric Cancer Companies such as Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
• Promising Gastric Cancer Therapies such as Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,  TCRx_T Cells,  IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,  PT 886, PRS-343, Oraxol, CA-4948,  Q702,  ACE1702, SI-B001, TT-4, LUM015,  LB 1908, CUE-102,  TORL-2-307-MAB,  OBI-833/OBI-821,  ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,  LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,  CCT303-406, VMD-928,  ITI 4000, PAb 001, and others.
• April 2024: Singlera Genomics Inc. aims to evaluate the clinical efficacy of polygene methylation (PCR-fluorescence probe) for adjunctive diagnosis of gastric cancer. The study assesses sensitivity across various types and stages of gastric cancer, specificity in distinguishing healthy controls and precancerous states, and potential interference with other cancer detections. Comparison with CA199, CEA, and CA724 will provide crucial insights, informing the development of future detection kits.
• March 2024: Vivian Wing Yan Lee conducts a retrospective cost-minimization analysis comparing treatment costs between EOF and EOX regimens for gastric cancer patients in Hong Kong. The study utilizes patient baseline characteristics and cost data extracted from records to assess economic implications. Notably, the Hong Kong Hospital Authority’s recent extension of subsidized Xeloda® therapy for colorectal cancer treatment serves as a contextual backdrop.
• February 2024: Bristol-Myers Squibb initiates a study to evaluate the efficacy and safety of relatlimab in combination with nivolumab and chemotherapy for unresectable, untreated locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. This Phase II clinical trial aims to compare the investigational drug’s effectiveness as a first-line treatment option against standard nivolumab plus chemotherapy regimens.
• February 2024: Ambrx Inc. launches a Phase 1, multicenter, open-label study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression. The study aims to establish the recommended Phase 2 dose (RP2D) and assess safety and anticancer activity in breast, gastric, and other advanced HER2-positive solid tumors.

 

Explore our comprehensive Gastric Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Gastric Cancer Pipeline Outlook

 

Gastric Cancer Overview

Gastric cancer, also known as stomach cancer, is a formidable adversary in the realm of oncology, characterized by the malignant growth of cells lining the stomach. This disease poses a significant global health burden, with varying incidence rates across different regions and populations. Gastric cancer often manifests silently, with symptoms appearing in advanced stages, making early detection and intervention crucial for successful treatment outcomes. Risk factors such as Helicobacter pylori infection, tobacco use, certain dietary habits, and genetic predisposition play pivotal roles in its development.

Diagnosis typically involves a combination of imaging studies, endoscopy, and biopsy, enabling healthcare professionals to determine the extent of the disease and formulate an appropriate treatment plan. Treatment modalities for gastric cancer encompass surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, often employed in a multidisciplinary approach tailored to individual patient needs. Despite advancements in diagnosis and treatment, gastric cancer remains a formidable challenge, underscoring the continued importance of research, early detection efforts, and comprehensive patient care strategies in combating this disease.

 

Gastric Cancer Emerging Drugs Profile

• Catumaxomab: Linton Pharm Co. Ltd.

Catumaxomab is a bispecific monoclonal antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell–and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects. It is co-developed by Trion Pharma and Neovii Biotech. Currently it is in Phase III stage of clinical trial evaluation to treat Gastric Cancer.

• HLX10: Shanghai Henlius Biotech

HLX10, a novel recombinant humanized anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius. The drug candidate works on programmed cell death-1 receptor antagonists and T lymphocyte stimulant mechanism of action. Currently being evaluated in the Phase III studies.

• FLX475: RAPT Therapeutics

FLX475 is an oral, small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues, without depleting Treg throughout the body. It is in collaboration agreement with Hanmi for specific regions like Korea, Taiwan and China. Currently the drug is being evaluated in Phase II for the treatment of Gastric Cancer.

• Savolitinib: AstraZeneca/HUTCHMED

Savolitinib is an oral, potent and highly selective MET tryokinase inhibitors (TKI). It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. The drug is been developed under global licensing and collaboration agreement with AstraZeneca. The drug is in Phase II stage of clinical trials.

• ASP 2138: Astellas Pharma

ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip route. The drug candidate is being developed based on XmAb technology. The drug is under clinical development by Xencor and currently drug is in Phase I stage of clinical trials for the treatment of gastric cancer.

• Minnelide : Minneamrita Therapeutics LLC

Minnelide is under clinical development by Minneamrita Therapeutics. It is administered through intravenous and oral routes. The drug candidate is a water soluble analogue of triptolide and is derived from the thunder God vine (Tripterygium wilfordii). It acts by targeting heat shock protein70 (Hsp70). Currently being investigated in a Phase I clinical trial in patients suffering with gastric cancer.

 

Dive into our Gastric Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Gastric Cancer Treatment Therapies

 

Gastric Cancer Therapeutics Assessment

There are approx. 180+ key companies which are developing the therapies for Gastric Cancer. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd.

 

DelveInsight’s Gastric Cancer pipeline report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Download the Gastric Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Gastric Cancer Clinical Trials Assessment

 

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 

Gastric Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Dive into our detailed Gastric Cancer Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Gastric Cancer Products, Companies, and Unmet Needs

 

Scope of the Gastric Cancer Pipeline Report

• Coverage- Global
• Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Gastric Cancer Companies- Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
• Gastric Cancer Therapies- Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,  TCRx_T Cells,  IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,  PT 886, PRS-343, Oraxol, CA-4948,  Q702,  ACE1702, SI-B001, TT-4, LUM015,  LB 1908, CUE-102,  TORL-2-307-MAB,  OBI-833/OBI-821,  ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,  LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,  CCT303-406, VMD-928,  ITI 4000, PAb 001, and others.

 

Gain valuable insights into emerging therapies and innovations with our Gastric Cancer Pipeline Report @ Gastric Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Gastric Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Catumaxomab : Neovii Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. FLX475: RAPT Therapeutics
12. Early Stage Products (Phase I)
13. Comparative Analysis
14. ASP 2138: Astellas Pharma
15. Inactive Products
16. Gastric Cancer Key Companies
17. Gastric Cancer Key Products
18. Gastric Cancer – Unmet Needs
19. Gastric Cancer – Market Drivers and Barriers
20. Gastric Cancer – Future Perspectives and Conclusion
21. Gastric Cancer Analyst Views
22. Gastric Cancer Key Companies
23. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/